Beijing You'an Hospital, Capital Medical University, Beijing 10069, China ; Department of Biological Sciences, The University of Texas at El Paso, El Paso, TX 79968, USA.
Beijing You'an Hospital, Capital Medical University, Beijing 10069, China.
J Immunol Res. 2014;2014:906532. doi: 10.1155/2014/906532. Epub 2014 May 14.
Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide. Although new therapeutic strategies have been continuously developed and applied to clinical treatment for HCC, the prognosis is still very poor. Thus, early detection of HCC may enhance effective and curative management. In this study, autoantibody responses to MDM2 protein in HCC patient's serum were evaluated by enzyme-linked immunosorbent assay (ELISA) and part sera were evaluated by Western blotting and indirect immunofluorescence assay. Immunohistochemistry (IHC) over tissue array slides was also performed to analyze protein expression of MDM2 in HCC and control tissues. The prevalence of autoantibodies against MDM2 was significantly higher than that in liver cirrhosis (LC), chronic hepatitis (CH), and normal human sera (NHS). The average titer of autoantibodies against MDM2 in HCC serum was higher compared to that in LC, CH, and NHS. A high titer of autoantibodies against MDM2 in ELISA could be observed in the serum in 6 to 9 months before the clinical diagnosis of HCC in the serum of several HCC patients with serial bleeding samples. Our preliminary data indicate that MDM2 and anti-MDM2 system may be a potential biomarker for early stage HCC screening and immunodiagnosis.
肝细胞癌 (HCC) 是全球第五大常见恶性肿瘤。尽管新的治疗策略不断被开发并应用于 HCC 的临床治疗，但预后仍然很差。因此，早期发现 HCC 可能会增强有效的治疗管理。在这项研究中，通过酶联免疫吸附试验 (ELISA) 评估了 HCC 患者血清中 MDM2 蛋白的自身抗体反应，部分血清通过 Western blot 和间接免疫荧光检测进行了评估。还通过组织阵列载玻片进行了免疫组织化学 (IHC) 分析以研究 HCC 和对照组织中 MDM2 蛋白的表达。针对 MDM2 的自身抗体的流行率明显高于肝硬化 (LC)、慢性肝炎 (CH) 和正常人血清 (NHS)。与 LC、CH 和 NHS 相比，HCC 血清中针对 MDM2 的自身抗体的平均滴度更高。在具有连续出血样本的几个 HCC 患者的血清中，可以在 HCC 临床诊断前 6 到 9 个月的血清中观察到 ELISA 中针对 MDM2 的高滴度自身抗体。我们的初步数据表明，MDM2 和抗 MDM2 系统可能是早期 HCC 筛查和免疫诊断的潜在生物标志物。
